The Market's Enigma: Syngene International Stock Soars 20% Amidst Q4 Profit Dip
Indian Pharma Eyes Major Gains as US BIOSECURE Act Targets Chinese Biotech
Syngene International's Stock Slide: Unpacking the Decline and Market Impact